Abstract
P-glycoprotein accounts for the most intrinsic and acquired cancer multidrug resistance. To inhibit the expression of P-glycoprotein is one of the effective ways to reverse cancer drug resistance. Honokiol, a naturally occurring compound, has been demonstrated to combat cancer through mechanisms including inhibition of angiogenesis and induction of apoptosis. Here, we show that honokiol down-regulated the expression of P-glycoprotein at mRNA and protein levels in MCF-7/ADR, a human breast MDR cancer cell line. The down-regulation of P-glycoprotein was accompanied with a partial recovery of the intracellular drug accumulation, and of the sensitivities toward adriamycin. This study reveals a novel function of honokiol as an anti-cancer agent.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
-
Antibiotics, Antineoplastic / pharmacology
-
Biphenyl Compounds / pharmacology*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Dose-Response Relationship, Drug
-
Down-Regulation / drug effects
-
Down-Regulation / genetics
-
Doxorubicin / pharmacology*
-
Drug Resistance, Multiple / genetics
-
Drug Resistance, Neoplasm / genetics
-
Drug Synergism
-
Drugs, Chinese Herbal / pharmacology
-
Flow Cytometry
-
Gene Expression Regulation, Neoplastic / drug effects*
-
Humans
-
Lignans / pharmacology*
-
Magnolia / chemistry
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
-
Rhodamine 123 / metabolism
-
Time Factors
Substances
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Antibiotics, Antineoplastic
-
Biphenyl Compounds
-
Drugs, Chinese Herbal
-
Lignans
-
RNA, Messenger
-
honokiol
-
Rhodamine 123
-
Doxorubicin